There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol Myers (BMY) and Becton Dickinson (BDX) with bullish sentiments.
Bristol Myers (BMY)
In a report released today, Geoff Meacham from Merrill Lynch maintained a Buy rating on Bristol Myers, with a price target of $75.00. The company’s shares closed last Wednesday at $54.36.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of 6.6% and a 58.5% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Kiniksa Pharmaceuticals, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $67.83, which is a 26.5% upside from current levels. In a report issued on March 26, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Becton Dickinson (BDX)
Stifel Nicolaus analyst Rick Wise maintained a Buy rating on Becton Dickinson today and set a price target of $265.00. The company’s shares closed last Wednesday at $223.88.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 6.0% and a 60.2% success rate. Wise covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Baxter International, and Intuitive Surgical.
Currently, the analyst consensus on Becton Dickinson is a Moderate Buy with an average price target of $268.90.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
